News

AQX-1125 is a small molecule activator of SHIP1, which is a regulating component of the PI3K cellular signaling pathway. The randomized, double-blind, multicenter, placebo-controlled Phase II KINSHIP trial

The randomized, double-blind, placebo-controlled Phase Ib trial is currently underway at Clinical Pharmacology of Miami. It is designed to further evaluate the safety, tolerability and pharmacokinetics of multiple-ascending

Remodulin Injection is indicated to treat patients with pulmonary arterial hypertension (PAH) via a pre-filled semi-disposable pump system. The company intends to launch the new subcutaneous Remodulin delivery

Inhalation of a non-sterile product with microbial contamination into the airways could increase the risk of respiratory infection. The risk is higher in patients who are immunocompromised (because

Tekmira today reported that: Enrolment of the target patient numbers in these Phase I/II studies has been completed; To date, 55 patients, in the both the Phase I

This study assesses a drug’s risk of QT prolongation and its proarrhythmic potential, and is a standard component of all clinical development programs for new molecular entities. Pyridorin

HPP is a genetic, chronic and progressive ultra-rare metabolic disease that can lead to destruction and deformity of bones, profound muscle weakness, seizures, respiratory failure and premature death.1-5

These countries include Bulgaria, the Czech Republic, Hungary, Poland, Romania, Slovakia and Slovenia. With this distributorship in place, Iclusig will be available to patients with resistant and intolerant

As part of the deal, Knight will pay around $1.75m cash as well as offer additional funding to further develop new pharmaceutical products. The deal will see establishment